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Abstract Previous studies have shown that Apaf-1 and caspase-
9 in the presence of cytochrome c and dATP can form an
initiating complex for an apoptotic protease cascade. We have
developed a cytochrome c-dependent in vitro system in which
caspases downstream of this initiation complex are activated.
The activation of caspase-9 from zymogen form to active dimeric
protease requires intrinsic enzymatic activity. In contrast,
caspase-3 and caspase-7 zymogens are proteolytically processed
by active caspase-9. Activation of the above caspases is blocked
by a dominant negative form of caspase-9. The in vitro system
displays surprising specificity in that other caspases, including 1,
2, 4, 8, 10, and 13, are not activated.
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Key words: Apoptosis; Cytochrome c ; dATP; Apaf-1;
Caspase; Cell-free
1. Introduction
Apoptosis, or programmed cell death, is an evolutionarily
conserved process central to the normal development and ho-
meostasis of multicellular organisms [1]. Previous genetic
studies of the nematode Caenorhabditis elegans identi¢ed three
core components of the cell death machinery: CED-3, CED-4
and CED-9. CED-3 and CED-4 function to kill cells whereas
CED-9 protects cells from death [2^6]. These central players
of cell death in the nematode are conserved in vertebrates.
CED-3 is equivalent to the emerging family of mammalian
cysteine proteases termed caspases that cleave substrates fol-
lowing an Asp residue [7^16]. CED-4 is a nucleotide binding
protein, potentially an ATPase, that possesses signi¢cant ho-
mology to the mammalian Apaf-1 [17,18]. CED-9 has se-
quence and functional similarity to anti-apoptotic members
of the mammalian Bcl-2 family [19^23]. CED-4 interacts
with the single polypeptide zymogen form of CED-3 and pro-
motes its autoprocessing to the active dimeric death protease.
CED-9 can either inhibit this process by binding to CED-4 or
directly blocking active CED-3 by acting as a pseudosubstrate
[18,24].
This molecular coupling of cell death components in the
worm is emulated in mammalian cells [3,25,26]. In response
to certain apoptotic stimuli, cytochrome c is released from
mitochondria [27^29]. The released cytochrome c induces
the formation of a caspase activating complex (CAC) in the
presence of dATP [25]. Present in the CAC is a mammalian
CED-4 homologue, Apaf-1, that directly binds the zymogen
form of caspase-9 via a homophilic interaction involving
CARD (caspase recruitment domain) motifs. The CARD do-
main is a collection of highly conserved residues in the amino
terminus of molecules recruited to complexes signaling apop-
tosis [30]. Once assembled, caspase-9 is activated by an un-
de¢ned mechanism. Active caspase-9 can proteolytically proc-
ess the zymogen form of downstream caspases, such as
caspase-3, leading to their activation [25,26]. However,
whether the processing of caspase-9 is through an autocata-
lytic mechanism and whether other caspases (especially other
CARD-containing caspases) are activated remains an open
question and is the subject of the present study.
Herein we report a simple in vitro system that demonstrates
cytochrome c-induced processing of caspase-9, downstream
activation of caspase-3 and -7 and cleavage of the death sub-
strate PARP (poly (ADP-ribose) polymerase) [31,32]. Impor-
tantly, the processing of caspase-9 from single polypeptide
zymogen to active dimeric protease was an autocatalytic event
dependent upon intrinsic protease activity. The processing of
the aforementioned caspases could be e¡ectively blocked by a
dominant negative (catalytically dead) version of caspase-9,
con¢rming that caspase-9 is upstream of caspase-3 and cas-
pase-7. Surprisingly, none of the other CARD-containing
caspases, including caspase-1, -2, -4, -8, -10 and -13, were
processed. These data suggest that the caspase cascade trig-
gered by cytochrome c and Apaf-1 possesses exquisite specif-
icity and leads only to the activation of caspase-3, -7 and -9.
The other CARD-containing caspases must be activated by a
di¡erent Apaf-1-like molecule or involve a totally di¡erent
mechanism.
2. Materials and methods
2.1. In vitro caspase activation assay
Rabbit reticulocyte lysates (TNT Quick T7 Master Mix, L1170)
were purchased from Promega. Typically, 4 Wl 35S-labeled caspase
or PARP was mixed with 6 Wl of TNT lysate or 6 Wl of in vitro
translated cold dominant negative caspase-9 in a 30 Wl reaction con-
taining processing bu¡er (20 mM HEPES-KOH, pH 7.5, 10 mM KCl,
1.5 mM MgCl2, 1 mM EDTA, 1 mM dATP (optional), 0.1 mM
PMSF (optional) and 1 mM DTT [25]). After addition of 0.2^0.5
Wg of cytochrome c (Sigma), the reactions were incubated at 30‡C
for 60^90 min. Samples were boiled in SDS sample bu¡er prior to
resolution by SDS-polyacrylamide electrophoresis. Labeled proteins
and their cleaved products were detected by autoradiography.
All expression constructs were epitope-tagged at their C-terminus
and have been described previously [33^36].
FEBS 20097 9-4-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 3 3 0 - 5
*Corresponding author. Fax: +1 (650) 225-6443.
E-mail: dixit@gene.com
1These authors contributed equally to this report.
2Fellow of the Medical Scientist Training Program, supported by the
MSTP NIH Training Grant 5T32 GM07863-16 and Pathology
Departmental Funds.
This work was supported by the National Institute of Health Grant
R01 AG13671.
FEBS 20097 FEBS Letters 426 (1998) 151^154
3. Results and discussion
3.1. Caspase-9 processing requires intrinsic protease activity
and an intact prodomain
To determine if reticulocyte lysate retained an ability to
respond to apoptotic stimuli, we asked if exogenously added
cytochrome c was capable of triggering processing of caspase-
9 zymogen. Surprisingly, caspase-9 was processed in a cyto-
chrome c-dependent manner (Fig. 1A; lanes 2, 4), presumably
via an endogenous Apaf-1-like activity that was present in the
lysate. Additional dATP was not required for this reaction to
proceed (Fig. 1A; lane 2). A truncated version of caspase-9
lacking the CARD-containing prodomain was not processed
(Fig. 1B; lane 4), consistent with a requirement for a CARD-
mediated interaction between caspase-9 and Apaf-1 [25,26].
Substantiating this notion, inclusion of the prodomain of cas-
pase-9 acted to signi¢cantly attenuate the processing of native
caspase-9 (Fig. 1C; lane 2). To determine whether the activa-
tion of caspase-9 was an autocatalytic process, a dominant
negative form in which the catalytic cysteine essential for ac-
tivity had been altered to an alanine was tested. This mutation
completely abolished caspase-9 processing (Fig. 2; lane 2 vs.
5), con¢rming that the activation of caspase-9 triggered by
cytochrome c required intrinsic catalytic activity.
3.2. Caspase-3 processing does not require intrinsic catalytic
activity and is blocked by dominant negative caspase-9
In response to cytochrome c, caspase-3 was processed (Fig.
3A; lane 2). Furthermore, a catalytically inert form of cas-
pase-3 (catalytic cysteine altered to alanine) was similarly
processed (Fig. 3A; lane 4), consistent with it being a target
of an upstream caspase, presumably caspase-9. In con¢rma-
tion of this, dominant negative caspase-9 (catalytic cysteine
mutant) was found to completely block the processing of cas-
pase-3 (Fig. 3B; lane 2). These observations suggest that the
in vitro system faithfully reproduced an apoptotic mechanism
that was responsive to cytochrome c.
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Fig. 1. Activation of caspase-9 in vitro. A: Caspase-9 is processed in a cytochrome c-dependent manner. The reactions containing 35S-labeled
caspase-9 were performed in the presence (+) or absence (3) of cytochrome c and dATP as indicated (see Section 2). Caspase-9 precursor and
its cleaved products are indicated on the right. The size markers are indicated on the left. B: Caspase-9-p30 is not processed. The reactions
containing 35S-labeled caspase-9 (lanes 1, 2) and a 35S-labeled truncated version, caspase-9-p30 (aa 140 C-terminus; lanes 3, 4) were performed
as described in Section 2. C: Caspase-9 processing is inhibited by its own prodomain. Four Wl of 35S-labeled caspase-9 were mixed with 6 Wl of
lysate either containing a vector or a construct expressing the prodomain of caspase-9 (aa 1^170) in a 30 Wl reaction as indicated. The reactions
were performed as described in Section 2.
Fig. 2. Caspase-9 processing requires intrinsic catalytic activity. 35S-
labeled caspase-9 (lanes 1^3) or its dominant negative version (cas-
pase-9 mut, lanes 4^6) were assayed. Only the large cleaved prod-
ucts are shown.
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3.3. Caspase-7 processing also does not require intrinsic
catalytic activity and is blocked by dominant negative
caspase-9
We asked whether other caspases would be activated di-
rectly or indirectly when the caspase cascade was triggered
by cytochrome c. Two non-CARD-containing caspases, cas-
pase-7 and caspase-6 (not shown) were tested. Caspase-7 was
found to be proteolytically processed (Fig. 4A; lane 2) and,
like caspase-3, a catalytically inactive form was similarly
cleaved (Fig. 4A; lane 6), suggesting that activation was likely
mediated by an active upstream caspase, potentially caspase-9.
In support of this, processing of caspase-7 was inhibited by
dominant negative caspase-9 (Fig. 4A; lanes 3 and 7).
3.4. Other caspases are not processed
In addition to caspase-9, caspase-1, -2, -4, -8, -10 and the
newly identi¢ed caspase-13 (unpublished) all contain a
CARD. These caspases are believed to be recruited to their
individual CACs via their CARDs [30]. It has been suggested
that one or more of these caspases might substitute for cas-
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Fig. 3. Caspase-3 processing in vitro. A: Both caspase-3 and its catalytically inactive form, caspase-3 mut, are cleaved. B: Cleavage of caspase-
3 is inhibited by dominant negative caspase-9 (caspase-9 DN). Four Wl of 35S-labeled caspase-3 were mixed with 6 Wl of lysate containing cold
protein from either a vector or a caspase-9 DN in vitro translation in a 30 Wl reaction.
Fig. 4. Cleavage of additional caspases and PARP. A: Caspase-7 processing triggered by cytochrome c. Both caspase-7 and its catalytically in-
active version (caspase-7 mut) were tested. Cleavage of caspase-7 is inhibited by dominant negative caspase-9 (A, lanes 3 and 7). B: Other
CARD-containing caspases are not processed. Caspase-1, -2, -4, -8 and -13 were tested and none of them were cleaved. C: PARP cleavage trig-
gered by cytochrome c. Full length PARP and its cleaved signature fragment are indicated.
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pase-9 in tissues where they are predominantly expressed [25].
Thus, we tested whether any of these caspases was proteolyti-
cally cleaved in response to cytochrome c. None of these
CARD-containing caspases was processed (Fig. 4B and not
shown), suggesting that the CAC composed of Apaf-1 and
cytochrome c was speci¢c for caspase-9. Consistent with
this, Apaf-1 does not interact with caspase-1, -2 and -8 [25]
(data not shown). It is therefore possible that activation of
other CARD-containing caspases may require their own spe-
ci¢c Apaf-1-like molecule or is achieved by a di¡erent mech-
anism. Poly (ADP-ribose) polymerase, or PARP, is one of the
hallmark death substrates that is cleaved when a cellular
apoptotic program is engaged. Cytochrome c-triggered cas-
pase activation led to the cleavage of PARP (Fig. 4C), con-
¢rming that the in vitro system using reticulocyte lysate can
recapitulate the entire apoptotic cascade from initiation of
caspase activation to cleavage of death substrates.
3.5. Concluding remarks
In response to cytochrome c, caspase-9 is proteolytically
processed through an autocatalytic mechanism, leading to ac-
tivation of downstream caspase-3 and caspase-7 and subse-
quent cleavage of the death substrate PARP. None of the
other caspases were processed. The caspase cascade triggered
by cytochrome c involves caspase-9 at the apex and caspase-3
and -7 as downstream e¡ectors.
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